US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SpyGlass Pharma, Inc.

26.50

+0.50001.92%

Post-market: 26.500.00000.00%19:30 EDT

Volume:101.10K

Turnover:2.66M

Market Cap:882.91M

PE:-15.81

High:26.81

Open:26.30

Low:25.34

Close:26.00

52wk High:32.44

52wk Low:17.06

Shares:33.32M

Float Shares:10.78M

Volume Ratio:1.14

T/O Rate:0.94%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6760

EPS(LYR):-17.9825

ROE:-67.71%

ROA:-37.23%

PB:3.80

PE(LYR):-1.47

Loading ...

Overview Company News Filings

Raymond James Initiates SpyGlass Pharma at Outperform, With $39 Price Target

MT Newswires Live

Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)

Spyglass Pharma Posts Corporate Deck on Long-Acting Intraocular Drug Delivery for Glaucoma, Ocular Hypertension Patients

SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained

SpyGlass Pharma Q2 FY26 Net Loss Widens to $19.9 Million; R&D Expenses Rise to $10.9 Million

Spyglass Pharma Q2 EPS USD -0.59

THOMSON REUTERS

Spyglass Pharma Q2 Pretax Profit USD -19.864 Million

THOMSON REUTERS

Stockland Reports Lapse of 42,313 Performance Rights

Solana price clears $80 resistance as technicals point to $90 next

Should Stockland’s A$250m Town Centre JV Shape the Income Story for ASX:SGP Investors?

Simply Wall St.

SpyGlass Pharma appoints Shannon Treviño as general counsel

Spyglass Pharma Appoints Shannon TreviÑO as General Counsel

THOMSON REUTERS

Is Stockland (ASX:SGP) Quietly Recasting Its Risk Profile With Morgan Stanley’s Capital-Light Partnership?

Simply Wall St.

Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing

THOMSON REUTERS

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)

SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat

SpyGlass Pharma to Participate in Upcoming Investor Conferences

Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)

Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/SGP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SGP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":26.5,"timestamp":1790884800000,"preClose":26,"halted":0,"volume":101101,"hourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":26.5,"latestTime":"19:30 EDT","volume":787,"amount":20855.5,"timestamp":1790897404765,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.019230769230769232,"floatShares":10781300,"shares":33317414,"eps":-1.676,"marketStatus":"Closed","change":0.5,"latestTime":"10-01 16:00:00 EDT","open":26.3,"high":26.81,"low":25.335,"amount":2664394.927194,"amplitude":0.056731,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":5,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":26,"preHourTrading":{"tag":"盘前","latestPrice":26,"preClose":26,"latestTime":"08:24 EDT","volume":2,"amount":52,"timestamp":1790857485614,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":26.5,"latestTime":"19:30 EDT","volume":787,"amount":20855.5,"timestamp":1790897404765,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.135446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","floatShares":10781300,"roa":"-37.23%","roe":"-67.71%","lyrEps":-17.982467,"volumeRatio":1.135446,"shares":33317414,"dividePrice":0,"high":26.81,"amplitude":0.056731,"preClose":26,"low":25.335,"week52Low":17.06,"pbRate":"3.80","week52High":32.44,"institutionHeld":0,"latestPrice":26.5,"eps":-1.676,"divideRate":0,"volume":101101,"delay":0,"ttmEps":-1.676,"open":26.3,"prevYearClose":16,"prevWeekClose":27.07,"prevMonthClose":26,"prevQuarterClose":26,"fiveDayClose":27.65,"twentyDayClose":28.28,"sixtyDayClose":20.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"SGP","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2026-05-14","symbol":"SGP","fiscalQuarterEnding":"2026/03","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.69},{"market":"US","date":"2026-03-26","symbol":"SGP","fiscalQuarterEnding":"2025/12","expectedEps":-6.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-5.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SGP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SGP","date":"2026-09-30","current":-15.745823,"percent":0.825397,"low":-21.652266,"twenty":-19.184491,"median":-16.309454,"eighty":-15.268591,"high":-14.017506,"avg":-16.927173,"sd":1.981387,"marketCap":850916585},"quantilePoints":[{"date":"2026-04-02","current":-20.423828,"twenty":-20.915203,"median":-19.976743,"eighty":-19.275615,"marketCap":814277598},{"date":"2026-04-10","current":-17.791054,"twenty":-19.887327,"median":-18.894548,"eighty":-18.2941,"marketCap":709311539},{"date":"2026-04-17","current":-20.985395,"twenty":-20.628232,"median":-19.259819,"eighty":-18.2941,"marketCap":836666721},{"date":"2026-04-24","current":-19.811622,"twenty":-20.628232,"median":-20.01284,"eighty":-18.750195,"marketCap":789869541},{"date":"2026-05-01","current":-19.233119,"twenty":-20.557806,"median":-19.76551,"eighty":-18.750195,"marketCap":766805217},{"date":"2026-05-08","current":-21.287223,"twenty":-20.628232,"median":-20.01284,"eighty":-18.869002,"marketCap":848700282},{"date":"2026-05-15","current":-20.348204,"twenty":-20.557806,"median":-19.991879,"eighty":-18.951807,"marketCap":811262538},{"date":"2026-05-22","current":-16.428664,"twenty":-20.542715,"median":-19.82839,"eighty":-18.248826,"marketCap":737055581},{"date":"2026-05-29","current":-16.634049,"twenty":-20.51924,"median":-19.719397,"eighty":-17.334564,"marketCap":663182890},{"date":"2026-06-05","current":-16.323837,"twenty":-20.485703,"median":-19.406541,"eighty":-16.365768,"marketCap":650815064},{"date":"2026-06-12","current":-15.166832,"twenty":-20.465581,"median":-18.98998,"eighty":-15.765344,"marketCap":604686416},{"date":"2026-06-18","current":-15.259057,"twenty":-20.45723,"median":-18.830682,"eighty":-15.591067,"marketCap":608363337},{"date":"2026-06-26","current":-14.017506,"twenty":-20.408703,"median":-18.172531,"eighty":-15.533886,"marketCap":628881407},{"date":"2026-07-02","current":-14.509349,"twenty":-20.348204,"median":-17.531147,"eighty":-15.527136,"marketCap":650947421},{"date":"2026-07-10","current":-14.956478,"twenty":-20.239211,"median":-16.634049,"eighty":-15.359666,"marketCap":671007434},{"date":"2026-07-17","current":-15.470677,"twenty":-20.105065,"median":-16.579363,"eighty":-15.259057,"marketCap":694076449},{"date":"2026-07-24","current":-15.560103,"twenty":-20.01284,"median":-16.428664,"eighty":-15.247112,"marketCap":698088452},{"date":"2026-07-31","current":-16.9313,"twenty":-19.979303,"median":-16.327675,"eighty":-15.249961,"marketCap":759605825},{"date":"2026-08-07","current":-14.762377,"twenty":-19.930676,"median":-16.460092,"eighty":-15.249961,"marketCap":827475536},{"date":"2026-08-14","current":-15.019457,"twenty":-19.846835,"median":-16.323837,"eighty":-15.098224,"marketCap":841885631},{"date":"2026-08-21","current":-15.651981,"twenty":-19.814976,"median":-16.231773,"eighty":-15.105016,"marketCap":877340489},{"date":"2026-08-28","current":-16.069685,"twenty":-19.737842,"median":-16.133919,"eighty":-15.15457,"marketCap":900754074},{"date":"2026-09-04","current":-17.29893,"twenty":-19.645616,"median":-16.12274,"eighty":-15.231056,"marketCap":969656911},{"date":"2026-09-11","current":-16.296439,"twenty":-19.568664,"median":-16.181307,"eighty":-15.249249,"marketCap":913464306},{"date":"2026-09-18","current":-17.501815,"twenty":-19.381917,"median":-16.296439,"eighty":-15.255703,"marketCap":981029224},{"date":"2026-09-25","current":-16.499324,"twenty":-19.253241,"median":-16.325756,"eighty":-15.28766,"marketCap":924836619},{"date":"2026-09-30","current":-15.180572,"twenty":-19.184491,"median":-16.309454,"eighty":-15.268591,"marketCap":850916585}],"updateTime":1790868269847},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659453081","title":"Raymond James Initiates SpyGlass Pharma at Outperform, With $39 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2659453081","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659453081?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:14","pubTimestamp":1786706042,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma (SGP) has an average rating of buy and mean price target of $44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJF","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659036143","title":"Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659036143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659036143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:50","pubTimestamp":1786704608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Ottobock SE & Co. KGaA (OBCKF), SpyGlass Pharma (SGP) and Fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-ottobock-se-co-kgaa-otherobckf-spyglass-pharma-nasdaq-sgp-and-figure-technology-solutions-inc-class-a-figr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-ottobock-se-co-kgaa-otherobckf-spyglass-pharma-nasdaq-sgp-and-figure-technology-solutions-inc-class-a-figr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0348788117.USD","BK4082","LCLG","FDNI","SG9999014492.USD","LU2065171402.SGD","LU0823038988.USD","LU2125910500.SGD","SE","BK4551","LU0251143029.SGD","LU2045819591.USD","IE0001KFT4U8.USD","SG9999004360.SGD","LU2008162690.USD","LU1242518931.SGD","LU0823039010.USD","LU0072462343.USD","LU0979878070.USD","LU0572939691.SGD","SG9999001135.SGD","SG9999002679.SGD","LU0516423091.SGD","BK4085","SG9999013486.USD","BK4588","IE0031814969.USD","LU0532188223.SGD","OBCKF","SG9999002604.SGD","SGXZ58947870.SGD","BK4166","SG9999002620.SGD","BK4007","LU0499858438.USD","LU1242518857.USD","LU0264606111.USD","LU0175139822.USD","LU1839390173.USD","LU2125910849.SGD","FGRS","LU2065171311.SGD","LU1048588211.SGD","BK4220","BK4581","NQmain","LU0516422952.EUR","LU0516422366.SGD","SGP","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659290270","title":"Spyglass Pharma Posts Corporate Deck on Long-Acting Intraocular Drug Delivery for Glaucoma, Ocular Hypertension Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2659290270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659290270?lang=en_us&edition=fundamental","pubTime":"2026-08-13 03:41","pubTimestamp":1786563701,"startTime":"0","endTime":"0","summary":"Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patientsSpyGlass outlined Phase 3 pivotal trials for its BIM-IOL System, designed to del","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLccG9tr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629675","title":"SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629675","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629675?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:45","pubTimestamp":1786135531,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Yi Chen reiterated a Buy rating on SpyGlass Pharma today and set a price target of $37.00. Yi Chen has given his Buy rating...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/spyglass-pharma-buy-rating-reiterated-as-late-stage-glaucoma-pipeline-advances-37-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/spyglass-pharma-buy-rating-reiterated-as-late-stage-glaucoma-pipeline-advances-37-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682776","title":"SpyGlass Pharma Q2 FY26 Net Loss Widens to $19.9 Million; R&D Expenses Rise to $10.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682776","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682776?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:37","pubTimestamp":1786048661,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma Q2 FY26 net loss widens to $19.9 million; R&D expenses rise to $10.9 millionSpyGlass Pharma posted a Q2 net loss of USD 19.9 million, or USD 0.59 per share, versus a loss of USD 8.7 mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbnJTCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657812657","title":"Spyglass Pharma Q2 EPS USD -0.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2657812657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657812657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046711,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNGC6P8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657534","title":"Spyglass Pharma Q2 Pretax Profit USD -19.864 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657534?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046711,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNGC6P8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650991199","title":"Stockland Reports Lapse of 42,313 Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2650991199","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650991199?lang=en_us&edition=fundamental","pubTime":"2026-07-09 06:57","pubTimestamp":1783551449,"startTime":"0","endTime":"0","summary":"An update from Stockland ( ($AU:SGP) ) is now available. Stockland has reported the lapse of 42,313 performance rights, designated as SGPAA securit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-42313-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-42313-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504313","title":"Solana price clears $80 resistance as technicals point to $90 next","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504313","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504313?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:09","pubTimestamp":1782990541,"startTime":"0","endTime":"0","summary":"Solana price has erased much of June’s decline by reclaiming the $80 level, with record transaction activity and a technical breakout driving fresh optimism.Solana price has reclaimed the $80 level after record network activity and governance upgrades boosted buying momentum.Technical indicators favor further gains, with the next major resistance and liquidation cluster sitting near $90.Analysts remain divided as bullish momentum strengthens, while some traders warn the rally still faces key resistance.According to crypto.news data, Solana  price traded around $81.3 at the time of writing, up nearly 10% over the past 24 hours after breaking above the psychological $80 barrier for the first time in weeks. The recovery followed a series of network milestones that revived investor sentiment, while the broader crypto market also benefited from improving risk appetite after June’s steep correction.The next technical hurdle sits near the 50% Fibonacci retracement around $79.3, which has alre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/solana-price-clears-80-dollar-resistance-as-90-next/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/solana-price-clears-80-dollar-resistance-as-90-next/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["SOL.USD.HKCC","BK4007","BK7083","SGP.AU","SOLZ","BK7105","GSOL","BK7510","SLON","SSK","SOLT","SOL.AU","SOLX","BK7087","SGP","BSOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645555075","title":"Should Stockland’s A$250m Town Centre JV Shape the Income Story for ASX:SGP Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645555075","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645555075?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:22","pubTimestamp":1782127345,"startTime":"0","endTime":"0","summary":"Earlier today, Stockland announced a partnership with a Morgan Stanley Real Estate Investing vehicle to co-develop three new town centres worth about A$250 million, while reiterating its FY26 funds-from-operations and distribution guidance supported by strong recent sales across key residential segments.\nA key takeaway is how the sharp increases in masterplanned-community and land-lease net sales appear to underpin confidence in Stockland’s income outlook despite a challenging property...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/should-stocklands-a250m-town-centre-jv-shape-the-income-stor","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/should-stocklands-a250m-town-centre-jv-shape-the-income-stor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765646.SGD","LU0390134368.USD","LU2089283258.USD","BK4516","BK7510","LU1074936037.SGD","ISBC","IE00BKVL7J92.USD","LU1989772923.USD","LU0912757837.SGD","BK4534","LU0971096721.USD","SGP","LU0053666078.USD","LU2089284900.SGD","LU2271345857.HKD","LU0106261372.USD","LU1064131342.USD","LU0795875169.SGD","LU2028103732.USD","LU1732799900.SGD","LU0098860793.USD","LU1732800096.USD","LU1244550494.USD","BK4581","LU0106831901.USD","LU0234570918.USD","LU2111349929.HKD","LU1548497426.USD","LU1244550577.SGD","LU0795875086.SGD","LU0267386448.USD","LU1720051108.HKD","LU1791710400.SGD","BK4007","LU1244550221.USD","LU2487616109.SGD","LU2357305700.SGD","LU0006306889.USD","LU1162221912.USD","LU0557290698.USD","LU0528227936.USD","BK4585","LU0314104364.USD","LU0158827781.USD","LU1720051017.SGD","LU1791710582.SGD","LU1988902786.USD","SGP.AU","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203898","title":"SpyGlass Pharma appoints Shannon Treviño as general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203898","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203898?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:02","pubTimestamp":1781524972,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma appointed Shannon Trevio as general counsel as it advances the BIM-IOL System through Phase 3 trials.Trevio most recently served as general counsel and corporate secretary at Inari Medical, helping guide its USD 4.9 billion acquisition by Stryker.She previously worked at Sugg Law Group advising early-stage companies, taught transactional law at Loyola Marymount University, and practiced at Latham & Watkins.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL2KVzfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LU0114720955.EUR","LU2468319806.SGD","GB00B4LPDJ14.GBP","BK4504","LU2089984988.USD","LU2404859741.USD","LU2362540622.SGD","LU1791710582.SGD","IE00B64PRP62.GBP","LU0882574055.USD","LU2404859667.USD","LU0432979614.USD","IE00BN0W2T93.GBP","LU0823417737.USD","LU1791710400.SGD","LU0289739699.SGD","LU0690374961.EUR","LU2506952097.USD","LU0950375773.USD","LU0058720904.USD","SYK","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU0690374615.EUR","SG9999014005.SGD","SG9999014021.USD","BK4566","BK4588","LU2506952170.USD","LU2210150020.SGD","BK4007","BK4112","LU2362541513.USD","LU2324357040.USD","BK4082","NDAQ","SGP","LU0314104364.USD","SG9999014013.SGD","SG9999014039.USD","LU0823417653.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2362541273.HKD","IE00B3QW5Z07.USD","LU2095319765.USD","GB00B4QBRK32.GBP","LU1983299246.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643080982","title":"Spyglass Pharma Appoints Shannon TreviÑO as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2643080982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643080982?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUABSWVC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643249505","title":"Is Stockland (ASX:SGP) Quietly Recasting Its Risk Profile With Morgan Stanley’s Capital-Light Partnership?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643249505","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643249505?lang=en_us&edition=fundamental","pubTime":"2026-06-14 16:17","pubTimestamp":1781425025,"startTime":"0","endTime":"0","summary":"In recent days, Stockland reported strong residential home-lot sales, record activity in its land-lease communities, and a new capital partnership with Morgan Stanley Real Estate Investing for neighbourhood shopping centres, supporting its capital-light growth approach.\nThese developments highlight how Stockland is using external capital and resilient housing demand to balance cyclical residential exposure with more stable, recurring property income.\nWe’ll now examine how this new Morgan...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/is-stockland-asxsgp-quietly-recasting-its-risk-profile-with","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/is-stockland-asxsgp-quietly-recasting-its-risk-profile-with","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0225283273.USD","LU2271345857.HKD","LU1162221912.USD","LU2089284900.SGD","LU0053666078.USD","LU2487616109.SGD","LU0106831901.USD","LU1732799900.SGD","BK4581","LU0098860793.USD","LU2089283258.USD","LU0882574139.USD","LU1720051017.SGD","LU1720051108.HKD","LU0210528500.USD","LU1989772923.USD","LU2264538146.SGD","BK7510","LU2023251221.USD","BK4534","LU0528227936.USD","BK4007","LU1988902786.USD","LU0106261372.USD","BK4585","AIPO","LU2111349929.HKD","LU1244550221.USD","LU1791710582.SGD","BK4504","LU0267386448.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU0006306889.USD","LU1363072403.SGD","LU0314104364.USD","LU2133065610.SGD","LU1244550577.SGD","LU1668664300.SGD","BK4588","LU1074936037.SGD","LU1989772840.SGD","SGP","SGP.AU","LU0971096721.USD","LU0320765646.SGD","LU0557290698.USD","LU1244550494.USD","BK7087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910404","title":"Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910404?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA1NHWQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948859","title":"SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948859","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948859?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., June  02, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305080/0/en/SpyGlass-Pharma-Appoints-Mike-Pinder-as-Vice-President-Marketing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639383622","title":"Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639383622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639383622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:40","pubTimestamp":1780054816,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on SpyGlass Pharma (SGP) and Fiserv (FISV). SpyGlass Pharma (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1823568750.SGD","NA","BK4588","BK4227","LU2125909759.SGD","LU2125909916.SGD","LU1861220207.SGD","SGP","BK4585","BK4106","BK4141","LU0354030438.USD","LU0980610538.SGD","LU0130103400.USD","LU1201861165.SGD","LU0320765489.SGD","LU1923622291.USD","FISV","LU0130102774.USD","LU0070302665.USD","LU0354030511.USD","BK4007","LU1046421795.USD","LU0648000940.SGD","LU1861217088.USD","LU0208291251.USD","LU1201861249.SGD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333415","title":"SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333415?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364824,"startTime":"0","endTime":"0","summary":"Spyglass Pharma executive management will take part in investor conference sessions on May 26, June 4, June 10.Events include fireside chats at the Stifel 2026 Virtual Ophthalmology Forum on May 26 and the Jefferies Global Healthcare Conference on June 4.A corporate presentation is scheduled for the Goldman Sachs 47th Annual Global Healthcare Conference on June 10.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7FFqJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","GSX","LU2237443622.USD","BK4112","LU0061475181.USD","LU0106831901.USD","LU1868836757.USD","LU1791807156.HKD","LU2750360997.AUD","SF","IE0004086264.USD","LU2471134796.USD","LU0096364046.USD","LU2237438978.USD","NDAQ","LU1894683348.USD","LU1894683264.USD","LU2471134952.CNY","LU0314104364.USD","LU0942090050.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU1868837300.USD","LU1868836914.USD","BK4127","LU2237443465.HKD","LU2237443549.SGD","LU2210150020.SGD","IE0034235188.USD","BK4550","BK4585","IE0004091025.USD","LU2471134523.USD","IE00BKPKM429.USD","SGP","IE00B3QW5Z07.USD","LU1804176565.USD","IE00BFXG1179.USD","LU2237443978.SGD","LU2750360641.GBP","BK4552","SG9999014005.SGD","BK4504","BK4007","IE00BN0W2T93.GBP","LU1668664300.SGD","LU0251142724.SGD","LU0251131958.USD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333066","title":"SpyGlass Pharma to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333066?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299275/0/en/SpyGlass-Pharma-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636586310","title":"Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586310?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:55","pubTimestamp":1779209724,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding maintained a Buy rating on SpyGlass Pharma today and set a price target of $62.00. Ding covers the Healthcare sector,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636733940","title":"Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636733940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636733940?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:04","pubTimestamp":1779105868,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}